Neurotrophic tyrosine kinase inhibitors: A review of implications for patients, clinicians and healthcare services

被引:4
|
作者
Walker, Andrew [1 ]
机构
[1] Calderdale & Huddersfield NHS Fdn Trust, Dept Pharm, Huddersfield, W Yorkshire, England
关键词
Neurotrophic tyrosine receptor kinase; larotrectinib; entrectinib; neurotrophic tyrosine receptor kinase inhibitor; oncology; ETV6-NTRK3 GENE FUSION; CANCER; TROPOMYOSIN; THERAPIES; PATHOLOGY; ONCOGENE; TRK;
D O I
10.1177/1078155220959428
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Neurotrophic tyrosine receptor kinase (NTRK) inhibitors represent the latest advancement as a treatment option in targeted therapies for malignant disease. NTRK gene fusions involving NTRK1, 2 or 3 are implicated as genetics drivers for a number of tumour types which arise within adult and paedatric patients. NTRK inhibitors (Larotrectinib and Entrectinib) are effective agents which have demonstrated clinical benefit in the treatment of NTRK fusion positive solid tumours. Larotrectinib represents the first targeted agent to receive approval from international authorisation and commissioning bodies for the treatment of a specific genetic expression indiscriminate of the site from which the tumour has arisen. As such NTRK inhibitors could pave the way for international healthcare bodies to adopt a similar approach for future targeted therapies thereby altering the manner in which healthcare providers and patients are able to access and utilise innovative, targeted treatment options in future. The potential implications of this new approach are likely to impact upon several aspects of the traditional authorisation and commissioning pathways with potential changes to the design of clinical trials, the review and approval process by regulatory bodies and immunohistopathology services.
引用
收藏
页码:2015 / 2019
页数:5
相关论文
共 50 条
  • [31] Glycemic Control in Patients Treated with Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia: A Systematic Review
    Spatafora, Laura
    Golemiec, Breanne
    Thabane, Lehana
    Banfield, Laura
    Hillis, Christopher M.
    Samaan, Constantine
    Athale, Uma
    BLOOD, 2018, 132
  • [32] Pulmonary Complications in Patients Treated with Tyrosine Kinase Inhibitors, a Systematic Review and Meta-Analysis
    Chai-Adisaksopha, Chatree
    Calvin, Diep
    Hillis, Christopher M.
    BLOOD, 2015, 126 (23)
  • [33] Monitoring and Improving Adherence to Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia: A Systematic Review
    Tan, Bee Kim
    Chong, Ping
    Chua, Siew Siang
    Chen, Li-Chia
    PATIENT PREFERENCE AND ADHERENCE, 2021, 15 : 2563 - 2575
  • [34] Cardiac monitoring in patients receiving tyrosine-kinase inhibitors
    Kennes, Soetkin
    Geraedts, Joost
    ACTA CLINICA BELGICA, 2016, 71 : 35 - 35
  • [35] Pulmonary Hypertension in Cancer Patients Treated with Tyrosine Kinase Inhibitors
    Patnaik, Soumya
    de Armas, Lissette R.
    Giza, Dana E.
    Balanescu, Dinu V.
    Donisan, Teodora
    Lopez-Mattei, Juan
    Kim, Peter
    Iliescu, Gloria
    Thompson, Kara
    Mouhayar, Elie
    Daver, Naval
    Durand, Jean-Bernard
    Cortes, Jorge E.
    Iliescu, Cezar
    JOURNAL OF CARDIAC FAILURE, 2019, 25 (08) : S149 - S150
  • [36] Comparative arrhythmia patterns among patients on tyrosine kinase inhibitors
    Wei, Chen
    Fazal, Muhammad
    Loh, Alexander
    Kapoor, Ridhima
    Gomez, Sofia Elena
    Shah, Shayena
    Rogers, Albert J. J.
    Narayan, Sanjiv M. M.
    Wang, Paul J. J.
    Witteles, Ronald M. M.
    Perino, Alexander C. C.
    Cheng, Paul
    Rhee, June-Wha
    Baykaner, Tina
    JOURNAL OF INTERVENTIONAL CARDIAC ELECTROPHYSIOLOGY, 2024, 67 (01) : 111 - 118
  • [37] Comparative arrhythmia patterns among patients on tyrosine kinase inhibitors
    Chen Wei
    Muhammad Fazal
    Alexander Loh
    Ridhima Kapoor
    Sofia Elena Gomez
    Shayena Shah
    Albert J. Rogers
    Sanjiv M. Narayan
    Paul J. Wang
    Ronald M. Witteles
    Alexander C. Perino
    Paul Cheng
    June-Wha Rhee
    Tina Baykaner
    Journal of Interventional Cardiac Electrophysiology, 2024, 67 : 111 - 118
  • [38] Arrhythmia Patterns in Patients Managed With and Without Tyrosine Kinase Inhibitors
    Wei, Chen
    Fazal, Muhammad
    Kapoor, Ridhima
    Cheng, Paul
    Rogers, Albert J.
    Perino, Alexander C.
    Narayan, Sanjiv M.
    Rhee, June W.
    Baykaner, Tina
    CIRCULATION, 2022, 146
  • [39] Management of toxicity in patients treated with tyrosine kinase inhibitors (TKI)
    Naglieri, Emanuele
    EJC SUPPLEMENTS, 2008, 6 (14): : 42 - 45
  • [40] Important Considerations for Real-World Analysis of Neurotrophic Tyrosine Receptor Kinase Fusion Cancer and Tropomyosin Receptor Kinase Inhibitors
    Brose, Marcia S.
    Hong, David S.
    Drilon, Alexander
    JCO PRECISION ONCOLOGY, 2023, 7